openPR Logo
Press release

Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight

06-30-2017 07:27 AM CET | Health & Medicine

Press release from: PNS Pharma

Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight

“Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Herceptin drug in clinical pipeline. Currently there are 4 biosimilars in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 3 biosimilar version of Herceptin are commercially available in India and Iran for the treatment of Breast cancer. The patent on Herceptin expired in 2014.

Trastuzumab or Herceptin is a recombinant DNA derived humanized monoclonal antibody that interferes with the HER2/Neu receptor. It is the most common biological therapy used particularly for breast cancer, against the Her2+ receptor which stands for Human Epidermal Growth Factor Receptor 2-positive. In some cancers, notably certain types of breast cancer, HER2 is over-expressed, and causes cancer cells to reproduce uncontrollably.

Download Report:

Herceptin as a single agent is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress the HER2 protein and who have received one or more chemotherapy regimens for their metastatic disease. Herceptin in combination with paclitaxel is indicated for treatment of patients with metastatic breast cancer whose tumors overexpress the HER2 protein and who have not received chemotherapy for their metastatic disease.

The mechanism of action of this drug is observed clearly in Breast cancer, as HER 2 is overexpressed allowing the cell proliferation in uncontrolled manner. The trastuzumab binds to the domain IV of the extracellular segment of HER2/Neu receptor and the drug causes the arrest during G1 phase of cycle, thus reduced proliferation and moreover, it down regulates the activation of AKT pathway too thus ending the uncontrolled cell differentiation.

Herceptin, one of Roche's three HER2+ breast cancer drugs, recorded a 15% sales increase in the US and a 10% rise overall. Sales were driven by longer duration of treatment in combination with Perjeta, another HER2+ breast cancer treatment from Roche, for both early and advanced breast cancer. China and Brazil also contributed to strong growth in Herceptin sales.

It costs around US$ 70,000 for full course treatment, thus allowing the big blockbuster for Roche with the sales of US$ 6.79 Billion in 2015; it is the drug that remained third best seller after about 15 years on the market. Roche has changed the trade name of the drug and has re-introduced an affordable version of the same in the Indian market. The new drug named Herclon would cost approximately INR 75,000 (US$ 1122) in the Indian market.

Biocon Limited, a pharmaceutical in India had received Marketing Authorization from the Drugs Controller General of India (DCGI) for its biosimilar Trastuzumab being developed jointly with Mylan, for the treatment of Her 2+ metastatic breast cancer. The regulatory approval for biosimilar Trastuzumab in India is the world’s first biosimilar version under the brand name of CANMAb.

For Report Sample Contact: or :Visit :

Recent Publication

* Global Peptide Therapeutics Market & Clinical Trials Insight
* Global Orphan Drug Clinical Pipeline Insight 2022

PNS Pharma is a pioneer in offering exclusive research reports for the pharmaceuticals industry. PNS Pharma offers Syndicated Research Reports on Drug Pipeline and Company Pipeline Analysis. These reports include comprehensive information related to the development of various drugs across clinical pipeline. Further, the reports include details on the originator, Owner, License, Chemical Formula, Patent Information, Phase of development, and Phase of development by country for each specific drug. The reports on company pipeline include all the drugs developed by particular companies across different therapeutic segments and phases and in different countries.

Rajesh Arora
PNS Pharma
8-9, Ansal Building
Dr. Mukherjee Nagar
Delhi, India

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight here

News-ID: 602944 • Views: 216

More Releases from PNS Pharma

Gene Therapy Market witnessing 35% Growth To Reach USD 8 Billion By 2026
The approach of modifying the genes directly to correct the disease linked with it is one of the most widely accepted and researched field in the pharmaceutical industry. Gene therapy holds significant potential to support various applications in the cancer research sector and other genetic linked diseases. The promising and potential approach of the therapy to treat numerous genetic diseases is making it a successful research sector. Another important potential
Global Gene Therapy Market To Witness Positive Outlook With More Than USD 8 Bill …
Gene therapy process has successfully gained popularity among the researchers all around the globe. Since its discovery, the primary driver of the market of the gene therapy process is considered to be its ability to alter the cause of the disease at the molecular level and that too precisely than the other available technologies. The technological advancements and the development in the gene delivery systems have developed a bright scope
Global Gene Therapy Market Size Sales To Surpass USD 8 Billion By 2026
" Global Gene Therapy Market Opportunity & Clinical Trials Insight 2026" Report Highlights: o Global Gene Therapy market Opportunity: > USD 8 Billion o Global Gene Therapy Pipeline:: > 1000 In Trials o Commercially Available Gene Therapies: 11 o US & Europe Are Key Markets Download Report: 1. Introduction to Gene Therapy 1.1 Gene Therapy: An Overview 1.2 History of Development 2. Gene Therapy & its Impact on Genetic Alterations 2.1 Gene Therapy as a Mastermind of Genetic Revolution
Global Breast Cancer Drug Market & Clinical Trial Insight 2025
" Global Breast Cancer Drug Market & Clinical Trial Insight 2025" Report Highlights: • Global Breast Cancer Drug Market: US$ 40 Billion Opportunity • Global Breast Cancer Drug Clinical Pipeline: More Than 550 Drugs • Marketed Breast Cancer Drugs: More Than 90 Drugs • Comprehensive Clinical Insight & Patent Information • Drug Trials, Pricing, Dosage, Cancer Prevalence Insight: 130 Graphs/Charts Download Report: The applied science research has marked tremendous advancements in cutting off the epidemic cancer scenarios all around the

All 5 Releases

More Releases for Herceptin

Antibodies Market 2026 | , Herceptin, and Humira (AbbVie) are successful drugs i …
Increasing adoption of therapeutic antibodies along with elevated rate of product approval in developing countries is propelling the growth of the global antibodies market. The market had surpassed US$ 104 Bn in 2016. Additionally, approval of monoclonal antibody products, combined with drug conjugates, antibody fragments, and therapeutic antibodies in key markets of Europe, Japan and the U.S. have boosted the growth of the market as well as inexpensive biosimilar antibody
Herceptin Biosimilar Market: Industry Insights, Challenges, CAGR Analysis and Wo …
This report studies the global market size of Herceptin Biosimilar in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Herceptin Biosimilar in these regions. This research report at InForGrowth categorizes the global Herceptin Biosimilar market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future
Herceptin Biosimilar Industry balanced to Reach Insignificant CAGR till 2023
Worldwide Market Reports added Latest Research Report titled “Global and Chinese Herceptin Biosimilar Industry, 2018 Market Research Report” to its Large Report database. The ‘Global and Chinese Herceptin Biosimilar Industry, 2013-2023 Market Research Report’ is a professional and in-depth study on the current state of the global Herceptin Biosimilar industry with a focus on the Chinese market. The report provides key statistics on the market status of the Herceptin Biosimilar manufacturers
United States Herceptin Biosimilar Market 2017
In this report, the United States Herceptin Biosimilar Market 2017 is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: The West Southwest The Middle Atlantic New England The South The Midwest with sales (volume), revenue (value), market share and growth rate of Herceptin Biosimilar in
Global Herceptin Biosimilar Market Research Depth Analysis with Opportunity Asse …
Herceptin Biosimilar Market Research Report Monitor Present's Global Herceptin Biosimilar Market 2017 Industry Trend Enhances The Decision Making Capabilities And Helps To Create An Effective Counter Strategies To Gain Competitive Advantage. Description The Global Herceptin Biosimilar Protein Report Offers A Comprehensive Evaluation Of The Global Herceptin Biosimilar Protein Industry. This Report Evaluates The Global Market For "Global Herceptin Biosimilar Protein". The Global Herceptin Biosimilar Protein Report Provides Complete Analysis Of The Global Herceptin
Global Herceptin Biosimilar Market Research Report 2017
Report Hive Market Research Released a New Research Report of 106 pages on Title " Global Herceptin Biosimilar Market Research Report 2017 "with detailed Analysis, Forecast and Strategies. In this report, the global Herceptin Biosimilar market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented